(.pdf) dr.ssa Antonella Ferro - Progettoeventi
(.pdf) dr.ssa Antonella Ferro - Progettoeventi
(.pdf) dr.ssa Antonella Ferro - Progettoeventi
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Phase III, randomised, controlled study of Lapatinib plus<br />
capecitabine versus capecitabine alone (study<br />
EGF100151)<br />
Patients with ErbB2-positive locally advanced or metastatic<br />
breast cancer that progressed after prior anthracycline, taxane<br />
and trastuzumab<br />
(N=399*)<br />
Lapatinib 1250 mg po<br />
qd continuously +<br />
capecitabine 2000 mg/m 2 /day<br />
po, Days 1–14 q3wk<br />
RANDOMISATION<br />
Treatment continued until progression<br />
Capecitabine 2500 mg/m 2 /day<br />
po, Days 1–14 q3wk<br />
*Planned 528; stopped at interim analysis, following achievement of primary endpoint<br />
1. Cameron et al. Breast Cancer Res Treat 2008; 2. Geyer et al. N Engl J Med 2006;355:2733–43
Change language